Azithromycin

Azithromycin is a macrolide antibiotic and the first member of the azalide subclass, distinguished by a fifteen-membered ring that contains a nitrogen atom. ^[2] It stops bacteria from multiplying by interfering with their ability to make proteins, and it is active against a broad range of organisms, including many Gram-positive and Gram-negative bacteria and atypical pathogens. ^[2]

It is used to treat middle-ear infections, sinusitis, strep throat, community-acquired pneumonia, and skin infections, as well as sexually transmitted infections such as chlamydia, where a single dose can be curative. ^[2] Beyond straightforward infections, it also has immune-modulating and anti-inflammatory effects that make it useful in chronic airway diseases such as cystic fibrosis and some forms of bronchiectasis. ^[3]

The drug was discovered in 1980 by a team of researchers at the pharmaceutical company Pliva in Zagreb, in what was then Yugoslavia, and later licensed to Pfizer, which marketed it worldwide as Zithromax. ^[2] Its distinctive pharmacology set it apart from earlier macrolides such as erythromycin.

Azithromycin's most notable feature is how it distributes in the body. It accumulates inside cells, particularly the immune cells that carry it to sites of infection, reaching tissue concentrations many times higher than in the blood, and it is eliminated slowly, with a half-life measured in days. ^[3] These properties are what allow a short course, such as five days or even a single dose, to keep working after the last tablet is taken.

Azithromycin is generally well tolerated, with digestive upset being the most common side effect, and it interacts with fewer other drugs than some related macrolides because it only weakly affects the CYP3A4 liver enzyme. ^[2] It can prolong the heart's QT interval, and a large study found a small increase in cardiovascular death during treatment, chiefly in people already at high cardiac risk. ^[4] It is a prescription-only medicine and is on the World Health Organization's List of Essential Medicines.

Azithromycin is prescription only. Common side effects are diarrhea, nausea, and abdominal cramps. It can prolong the QT interval and, rarely, trigger dangerous heart rhythms, so it is used carefully in people with heart disease or on other QT prolonging drugs. It can rarely strain the liver and cause hearing changes with high or prolonged dosing. A plus is that it has far fewer drug interactions than erythromycin or clarithromycin because it does not strongly block the CYP3A4 enzyme. People with a macrolide allergy should avoid it.

Rifampicin is a potent hepatic enzyme inducer that accelerates azithromycin metabolism, reducing plasma azithromycin levels by 50-62% ^[5]. This is a pharmacokinetic interaction where rifampicin increases azithromycin's metabolic clearance; peak drug concentrations (Cmax) and trough levels both decline substantially. The clinical consequence is reduced antibiotic efficacy; patients receiving both drugs may require azithromycin dose adjustment or increased dosing intervals to maintain therapeutic levels. Therapeutic drug monitoring has been used successfully to guide dosing in this interaction.

Azithromycin carries well-documented risk of QT interval prolongation and torsades de pointes, a potentially fatal cardiac arrhythmia ^[6]. This effect is pharmacodynamic, caused by azithromycin's blockade of cardiac potassium channels (hERG inhibition) that normally repolarize the heart. Elderly patients face substantially higher cardiac risk ^[7]. Most other azithromycin interactions remain inadequately studied in the clinical literature.

Checking a whole stack? Run it through interactions + stacks.

Azithromycin was discovered in 1980 by a team of researchers at the Croatian pharmaceutical company Pliva, led by Gabra Kobrehel, Gorjana Radobolja-Lazarevic, Zrinka Tamburasev, and Slobodan Djokic, who created it by inserting a nitrogen atom into the macrolide ring of erythromycin to form the first of a new subclass called the azalides. Pliva patented the molecule in 1981, and Pfizer subsequently licensed it for major world markets, launching it as Zithromax in the early 1990s. The structural modification gave the drug much greater acid stability and a far longer tissue half-life than erythromycin, enabling the short dosing courses for which it became known. It went on to become one of the most widely prescribed antibiotics in the world.

Azithromycin is widely regarded as a landmark of modern antibiotic development and remains one of the most trusted macrolides in everyday practice. Clinicians value its convenience, since a three- to five-day course, and in some cases a single dose, can treat infections that once required longer regimens, which helps patients complete therapy. Beyond its antibacterial reach, it has earned lasting scientific interest for its anti-inflammatory and immunomodulatory properties, now used to reduce exacerbations in chronic lung conditions such as cystic fibrosis and COPD. It is included on the World Health Organization's List of Essential Medicines, a mark of its recognized value; prescribers do weigh its potential to prolong the QT interval in susceptible patients.